Atlas Trials

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients

Clinical trial NCT04502680 · UNKNOWN

Trial details

NCT number
NCT04502680
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2021-06-01
Primary completion
2023-06-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.